<DOC>
	<DOCNO>NCT00331123</DOCNO>
	<brief_summary>This study design evaluate efficacy safety testosterone patch treatment low libido surgically menopausal woman take estrogen therapy .</brief_summary>
	<brief_title>Study Transdermal Testosterone Patches Surgically Menopausal Women With Low Libido</brief_title>
	<detailed_description>Women hypoactive sexual desire disorder ( HSDD ) undergone bilateral salpingo-oophorectomy hysterectomy randomize 52-week , multicenter , multinational study include 24-week , double-blind ( DB ) , parallel-group , placebo-controlled period follow 28-week open-label ( OL ) period . Patients stratify base use oral transdermal ET randomize receive placebo testosterone transdermal system . Patients maintain stable dose estrogen throughout study . Upon completion DB period , patient receive placebo switch TTS , active cohort remain active treatment . All patient follow additional 28 week safety . Patients complete first 52 week study give opportunity participate open label extension ( Years 2 , 3 , 4 ) , add protocol amendment . Safety assess adverse event , lipid , serum chemistry hepatic , renal carbohydrate metabolism evaluation , coagulation testing , hematology . Physical exam include clinical assessment facial hair acne monitor .</detailed_description>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Eligible woman must : 1 . Be 2070 year old generally good health 2 . Have undergone hysterectomy removal ovary least 6 month prior screen 3 . Be receive stable dose estrogen replacement therapy least 3 month prior screen intention maintain regimen . 4 . Be , judgment , stable monogamous sexual relationship perceive secure communicative , least one year prior study entry . 5 . Meet criterion hypoactive sexual desire disorder . Eligible woman must : 1 . Have receive androgen therapy time past 3 month ( past 7 month therapy investigational implantable product ) 2 . Be experience chronic acute life stress relate major life change 3 . Be experience depression and/or receive medication illness disorder 4 . Have current severe skin problem ( severe cystic acne ) allergy adhesive ( like one bandage ) 5 . Have major illness , active gall bladder disease , gynecological breast surgery within last 6 month 6 . Have history breast , endometrial , gynecological cancer time study participation cancer within last 5 year 7 . Have diabetes , history cerebrovascular disease , thromboembolic disorder , heart attack , angina time study participation thrombophlebitis within last 5 year 8 . Have abnormal laboratory test result upon initial screen study 9 . Have previously participate P &amp; GP study 1999068 1999092 10 . Have previously participate clinical trial within 30 day receive investigation medication within 30 day .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Surgical menopause</keyword>
	<keyword>HSDD</keyword>
</DOC>